{
    "2021-11-11": [
        [
            {
                "time": "2022-11-11",
                "original_text": "凯莱英11月11日大宗交易成交208.54万元",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "大宗交易",
                        "成交额"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-11-11",
                "original_text": "A股共发生201宗大宗交易成交45.76亿元（11月11日）",
                "features": {
                    "keywords": [
                        "A股",
                        "大宗交易",
                        "总成交额"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-11-11",
                "original_text": "凯莱英现1笔大宗交易 共成交208.54万元",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "大宗交易",
                        "单笔成交"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-11-11",
                "original_text": "凯莱英今日大宗交易成交0.51万股，成交价408.9元溢价0.0%",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "大宗交易",
                        "成交量",
                        "成交价",
                        "溢价率"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2022-11-11",
                "original_text": "医药生物行业《关于推动原料药产业高质量发展实施方案的通知》政策点评：提升产业全球竞争力 API板块性价比凸显",
                "features": {
                    "keywords": [
                        "医药生物",
                        "政策",
                        "原料药",
                        "高质量发展",
                        "全球竞争力",
                        "API板块"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2022-11-11",
                "original_text": "21健讯Daily｜未接种新冠疫苗重症和死亡几率高15倍；凯莱英即将在港二次上市",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "重症",
                        "死亡率",
                        "凯莱英",
                        "港股二次上市"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}